» Scientists pinpoint new vaccine "booster" that promotes potent anti-tumour immunity
10/05/24 08:00 from Breaking World Pharma News
Scientists from Trinity College Dublin have made an important breakthrough that offers promise for developing new immune therapies for cancer. They have discovered that a vaccine adjuvant - or "booster" - called C100 promotes potent anti...

» New treatment could reverse hair loss caused by an autoimmune skin disease
09/05/24 08:00 from Breaking World Pharma News
Researchers at MIT, Brigham and Women's Hospital, and Harvard Medical School have developed a potential new treatment for alopecia areata, an autoimmune disorder that causes hair loss and affects people of all ages, including children. F...

» AI predicts tumor-killing cells with high accuracy
08/05/24 08:00 from Breaking World Pharma News
Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer immunotherapies. Combined with additional algorithm...

» Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
07/05/24 08:00 from Breaking World Pharma News
Novartis announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts focused on developing novel radioligand therapies (RLTs) to treat cancers w...

» Participants of pioneering CRISPR gene editing trial see vision improve
06/05/24 08:00 from Breaking World Pharma News
About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published today in the New England...

» Drug targeting RNA modifications shows promise for treating neuroblastoma
03/05/24 08:00 from Breaking World Pharma News
Neuroblastoma is a common pediatric cancer that originates in developing nerve cells outside the brain. While increasingly intensive treatments have improved the survival of patients with high-risk neuroblastoma, currently more than 40% ...